NLS Pharmaceutics Reports Results From Study KO-874 On Mazindol's Neuroprotective Effects In Narcoleptic-Like Rat Model

Author: Benzinga Newsdesk | May 28, 2024 08:07am

NLS Pharmaceutics Ltd. (NASDAQ:NLSP)(NASDAQ:NLSPW) ("NLS" or the "Company"), a Swiss clinical-stage biopharmaceutical company dedicated to pioneering therapies for rare and complex central nervous system disorders, today announced promising results from its preclinical study KO-874 at the American Society of Clinical Psychopharmacology (ASCP) in Miami. This study evaluated the neuroprotective effects of mazindol on nocturnal activity in a rat model with narcoleptic-like symptoms induced by orexin-B-saporin (OX-B-SAP) lesions in the lateral hypothalamus (LH).

Posted In: NLSP NLSPW